Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note released on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their target price on Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating on the stock in a research note on Wednesday, August 7th.

Minerva Neurosciences Stock Up 5.6 %

NERV opened at $2.76 on Friday. The company’s 50-day moving average price is $2.94 and its 200 day moving average price is $2.85. Minerva Neurosciences has a fifty-two week low of $2.26 and a fifty-two week high of $13.49. The firm has a market cap of $19.26 million, a price-to-earnings ratio of -0.62 and a beta of 0.15.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). Research analysts anticipate that Minerva Neurosciences will post -2.26 earnings per share for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.